• Dogwood Therapeutics outlined two lead non-opioid pain and neuropathy programs, with Halneuron injection in Phase 2b for chemotherapy-induced neuropathic pain (CINP) and data anticipated in 3Q26.
• Halneuron, a tetrodotoxin-based NaV1.7 sodium channel blocker delivered by subcutaneous injection, is positioned for moderate-to-severe CINP; End-of-Phase 2 FDA submission targeted for 4Q26.
• SP16, an LRP1 activator, has an FDA-accepted IND for chemotherapy-induced peripheral neuropathy; Phase 1b enrollment expected to start mid-2026.
• Corporate snapshot showed cash of USD 13.2 million on a March 31, 2026 pro forma basis; shares outstanding 33,629,553.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.